Vansh Remedies

Vansh Remedies, established in 1991, is a pharmaceutical company headquartered in Vadodara, Gujarat, India. The company specializes in the manufacturing of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Under the directorship of Mr. Jagdish Patel, Vansh Remedies has evolved from a modest beginning to a prominent position in Gujarat's contract manufacturing sector. Mr. Patel's leadership has been instrumental in the company's growth, combining business acumen with professional experience in the pharmaceutical field.

The company operates as a partnership, with Mr. Vinit Patel serving as a key partner. Vansh Remedies is registered under the Goods and Services Tax (GST) in Gujarat, with the GST number 24AAOFV5773H1ZN. The firm's revenue for the fiscal year 2022-2023 was approximately $400,000 USD, derived from eight export shipments. The product portfolio comprises two primary products across two therapeutic categories, with a concentration on antifungals and advanced antibiotics.

Vansh Remedies operates manufacturing facilities in Vadodara, Gujarat, India. The plant specializes in the production of various pharmaceutical formulations, including tablets, capsules, syrups, and injections. While specific production capacities are not publicly disclosed, the company's focus on contract manufacturing indicates a facility capable of handling diverse production requirements. The plant's specialization in these dosage forms underscores its commitment to quality and compliance with industry standards.

The leadership of Vansh Remedies is characterized by experienced professionals dedicated to the company's mission. Mr. Jagdish Patel serves as the Managing Director, providing visionary leadership and strategic direction. Mr. Vinit Patel is a key partner, contributing to the company's operations and growth. The leadership team's combined expertise in the pharmaceutical industry has been pivotal in establishing Vansh Remedies as a reputable manufacturer of pharmaceutical formulations.

Vansh Remedies has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's export data indicates shipments to various countries, suggesting compliance with international regulatory standards. For instance, in July 2024, Vansh Remedies exported pharmaceutical products to Uzbekistan, indicating adherence to the regulatory requirements of the destination country. While specific regulatory filings and approvals are not detailed, the company's export activities imply a commitment to meeting the standards of these markets.

Vansh Remedies has expanded its reach into emerging markets, including Africa, Latin America, and Southeast Asia. The company's export data reveals shipments to countries such as Ghana, Ivory Coast, Uzbekistan, Yemen, and Tanzania. For example, in October 2024, Vansh Remedies exported pharmaceutical products to Ghana, indicating market penetration in the region. Additionally, the company's product range includes suppositories, which are essential in various therapeutic areas, potentially facilitating access to these emerging markets.

Vansh Remedies' geographic strategy demonstrates a focus on both domestic and international markets. The company's export activities to countries in Africa, Latin America, and Southeast Asia reflect a strategic approach to market diversification. However, the concentration of export value in a limited number of products suggests a potential risk associated with over-reliance on specific markets and product lines. To mitigate this, the company may consider expanding its product portfolio and exploring additional markets to achieve a more balanced and resilient geographic footprint.

Specific details regarding Vansh Remedies' interactions with the U.S. Food and Drug Administration (FDA), such as facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history, are not publicly available. The company's export data does not explicitly indicate shipments to the United States, suggesting that Vansh Remedies may not currently have a direct presence in the U.S. market. This absence could be due to various factors, including regulatory challenges or strategic business decisions. To enter the U.S. market, Vansh Remedies would need to comply with FDA regulations, which may involve obtaining necessary approvals and certifications.

Information regarding Vansh Remedies' compliance with World Health Organization (WHO) prequalification, European Union Good Manufacturing Practice (EU GMP) certificates, and European Directorate for the Quality of Medicines & HealthCare (EDQM) status is not publicly disclosed. The company's export data indicates shipments to countries that may require such certifications, suggesting that Vansh Remedies may adhere to international quality standards. However, without explicit confirmation, it is advisable for potential partners and clients to verify the company's compliance with these certifications before engagement.

Vansh Remedies operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company holds a manufacturing license issued by the CDSCO, authorizing it to produce pharmaceutical formulations. Additionally, Vansh Remedies has obtained necessary approvals from state drug controllers and export No Objection Certificates (NOCs), facilitating its export activities. The company's GST registration further indicates compliance with Indian regulatory requirements.

As of March 2026, there are no publicly available records indicating that Vansh Remedies has received any Form 483 observations, warning letters, or import alerts from regulatory authorities. The absence of such records suggests that the company maintains a good standing with regulatory bodies. However, it is recommended for stakeholders to conduct thorough due diligence to ensure ongoing compliance with all applicable regulations.

Vansh Remedies operates in a competitive pharmaceutical industry, facing competition from both domestic and international manufacturers. While specific competitors are not identified in the available data, the company's focus on antifungals and advanced antibiotics places it in direct competition with other manufacturers specializing in these therapeutic categories. The company's export activities to emerging markets indicate a strategic approach to capturing market share in regions with growing pharmaceutical demand. To enhance its competitive position, Vansh Remedies may consider expanding its product portfolio and strengthening its presence in key markets.

Vansh Remedies' key differentiators include its specialization in finished pharmaceutical formulations and a diverse product portfolio encompassing tablets, capsules, syrups, and injections. The company's focus on contract manufacturing in Gujarat has established it as a significant player in the region. Additionally, the inclusion of suppositories in its product range positions Vansh Remedies to meet specific therapeutic needs, potentially setting it apart from competitors.

Vansh Remedies' current strategic direction emphasizes the manufacturing and marketing of high-quality pharmaceutical formulations for both domestic and international markets. The company's mission to prevent and cure diseases, ease suffering, and enhance the quality of life aligns with its focus on contract manufacturing and product diversification. Looking ahead, Vansh Remedies may explore opportunities in generics, specialty drugs, biosimilars, and Contract Development and Manufacturing Organizations (CDMO) services to further strengthen its market position and drive growth.

Vansh Remedies demonstrates a consistent track record in its export activities, with a total export value of $400,000 USD from eight shipments. The company's export data indicates transactions with various international buyers, including A & Z Life Science Ltd in Ghana and LLC Emir Pharma in Uzbekistan. For instance, in October 2024, Vansh Remedies exported pharmaceutical products to Ghana, and in July 2024, it shipped products to Uzbekistan. These consistent export activities reflect the company's reliability and commitment to meeting international demand.

Importers should verify the following certifications when considering products from Vansh Remedies:

• FDA Approval: Confirm that the products are approved by the U.S. Food and Drug Administration (FDA) for sale in the United States. Verification can be done through the FDA's official website or by contacting the company directly.

• WHO-GMP Certification: Ensure that the manufacturing facility complies with World Health Organization Good Manufacturing Practice (WHO-GMP) standards. This can be verified by checking the WHO's official list of prequalified manufacturers.

• EU GMP Certification: Check that the facility holds European Union Good Manufacturing Practice (EU GMP) certification. Verification can be done through the European Medicines Agency (EMA) or the European Directorate for the Quality of Medicines & HealthCare (EDQM).

• ISO Certification: Verify that the company holds relevant International Organization for Standardization (ISO) certifications, such as ISO 9001 for quality management systems. This information is typically available on